Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BibbInstruments ABFRA:V0R -0.61%21 3-Year EBITDA Growth Rate is 10.90% as of Jun. 2026, which is 6% below its 10-year median of 11.55. GuruFocus rates FRA:V0R with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 688 Medical Devices & Instruments companies, BibbInstruments AB ranks better than 52.62% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 10.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 9.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of BibbInstruments AB was 24.30% per year. The lowest was -4.50% per year. And the median was 11.55% per year.
BibbInstruments AB (FRA:V0R) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
BibbInstruments AB 3-Year EBITDA Growth Rate Related Terms
FRA:V0R vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, BibbInstruments AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BibbInstruments AB 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, BibbInstruments AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where BibbInstruments AB's 3-Year EBITDA Growth Rate falls into.
BibbInstruments AB 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 10.90% mean?
BibbInstruments AB (FRA:V0R) has a 3-Year EBITDA Growth Rate of 10.90% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for BibbInstruments AB and its competitors. This is near median its historical median of 11.55. According to the industry distribution chart, BibbInstruments AB ranks #326 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 47.4%.
Is BibbInstruments AB's 3-Year EBITDA Growth Rate too high?
BibbInstruments AB's current 3-Year EBITDA Growth Rate of 10.90% is near median its 10-year median of 11.55. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. BibbInstruments AB's value of 10.90% is 34.6% above this industry median. Based on the distribution chart, BibbInstruments AB ranks #326 out of 688 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, BibbInstruments AB has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does BibbInstruments AB's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, BibbInstruments AB ranks #326 out of 688 companies for 3-Year EBITDA Growth Rate. This puts BibbInstruments AB in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.10. BibbInstruments AB's value of 10.90% is 34.6% above this benchmark. While the company's 10-year median is 11.55 vs. the industry median of 8.10, BibbInstruments AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BibbInstruments AB's current 3-Year EBITDA Growth Rate of 10.90% is 34.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for BibbInstruments AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BibbInstruments AB's current 3-Year EBITDA Growth Rate is 10.90%, which is near median its own 10-year median of 11.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BibbInstruments AB stock overvalued right now?
BibbInstruments AB (FRA:V0R) has a current 3-Year EBITDA Growth Rate of 10.90%. The current 3-Year EBITDA Growth Rate is 10.90%, which is near median its 10-year median of 11.55 and 34.6% above the Medical Devices & Instruments industry median of 8.10. BibbInstruments AB's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For BibbInstruments AB (FRA:V0R), the current 3-Year EBITDA Growth Rate is 10.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BibbInstruments AB develops disposable biopsy instrumentation under the brand EndoDrill for early detection of cancer tumors, especially in deep-tissue tumors. The product portfolio includes six disposable instruments based on the patented EndoDrill technology and a novel biopsy method still under development. The instruments will be used for tissue sampling (biopsy) of the most common types of cancer, for example; lung, breast, colorectal, prostate and stomach cancer.
21GF Score
Get the complete analysis for FRA:V0R
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:V0R has been successfully added to your 
